Eplerenone - A novel selective aldosterone blocker

Annals of Pharmacotherapy

Volumn 36, Issue 10, 2002, Pages 1567-1576

  Zillich, Alan J ^a   Carter, Barry L ^a   Suárez, Encarnación C ^a   Le Duff, Michel ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Eplerenone; Heart failure; Hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; PLACEBO; SPIRONOLACTONE;

CHRONIC DISEASE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOTENSION; MEDLINE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0036786124     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C027     Document Type: Review

References (73)

1. Corvol P, Claire M, Oblin ME, Geering K, Rossier B. Mechanism of the antimineratocorticoid effects of spirolactones. Kidney Int 1981;20:1-6.
2. Laragh JH. Spironolactone for the treatment of hypertension or congestive heart failure: a review. Princeton, NJ: Excerpta Medica, 1987.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
4. Weber WT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
5. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
6. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14:186-94.
7. Hameedi A, Chadow HL. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Curr Hypertension Rep 2000;2:378-83.
8. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001;37:677-88.
9. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001;3:240-8.
10. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37(2 pt 2):801-5.
11. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975; 97:52-8.
12. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
13. Rabasseda X, Silvestre JS, Castaner J. Eplerenone. Drugs Future 1999; 24:488-501.
14. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
15. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.
16. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
17. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
18. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342: 821-8.
20. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
21. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91.
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
24. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
26. Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, et al. Captopril in heart failure. A double blind controlled trial. Br Heart J 1984;52:530-5.
27. MacFayden RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
28. Struthers AD. Pathophysiology of aldosterone and its antagonists. Fundam Clin Pharmacol 2000;14:549-52.
29. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
30. Ullian ME, Islam MM, Robinson CJ, Fitzgibbon WR, Tobin ET, Paul RV. Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997;272(3 pt 2):H1454-61.
31. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33(1 pt 2):232-7.
32. Horiuchi M, Nishiyama H, Hama J, Takenaka T, Kondo H, Kino H, et al. Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 1993;264(2 pt 2):F286-91.
33. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-8.
34. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101.
35. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978;14:228-35.
36. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
37. Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 2000;165:533-6.
38. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995;290:69-73.
39. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.
40. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269(4 pt 1): E657-62.
41. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21(6 pt 2):929-33.
42. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
43. MacFadyen RI, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
44. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
45. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
46. + channels. Steroids 1995;60:114-9.
47. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
48. Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990;16:827-31.
49. Delyani JA, Rocha R, Cook CS, Tobert DS, Levin S, Roniker B, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001;19:185-200.
50. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.
51. Martin J, Krum H. Eplerenone (GD Searle & Co.). Curr Opin Investig Drugs 2001;2:521-4.
52. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141:3871-8.
53. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72.
54. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-54.
55. Delyani JA, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosterone antagonist (abstract). Am J Hypertens 1998; 11:94A.
56. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats (abstract). Hypertension 1998;32:598A.
57. Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis (abstract). Am J Hypertens 1998;11:94A.
58. Izzo JL Jr, Black HR, eds. Hypertension primer. 2nd ed. Baltimore: Lippincott, Williams, and Wilkins 1999.
59. Micromedex. Spironolactone - drug evaluation. Online Health Care Series. [cited 2002 Mar 18]. Available from:URL:http://www.micromedex.com/products/hcsonline/.
60. Roniker B. Eplerenone, a selective antagonist of the aldosterone receptor (abstract). Hypertension 1997;30:995.
61. Epstein M, Menard J, Alexander JC, Roniker B. Eplerenone, a novel and selective aldosterone receptor antagonist: efficacy in patients with mild to moderate hypertension (abstract). Circulation 1998;98(suppl): 198-9.
62. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
63. Data on file. Efficacy and safety of eplerenone-010. Skokie, IL: Pharmacia Corp.
64. Pratt JH, Flack JM, Wright JT, Patron A, Roniker B, Kuse-Hamilton J, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients (abstract). Am J Hypertens 2002;15 (part 2):213A.
65. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
66. Pitt B, Reichek N, Metscher B, Phillips R, Roniker B, Kleiman J, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy (abstract). Am J Hypertens 2002;15(part 2):23A.
67. Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study in patients with heart failure (abstract). J Am Coll Cardiol 1999;33:S188A-9A.
68. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, et al. Prognostic evaluation of neurohormonal plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42.
69. Berger R, Stanek B, Frey B, Sturm B, Huelsmann M, Bergler-Klein J, et al. B-type natriuretic peptides (BNP and PRO -BNP) predict longterm survival in patients with advanced heart failure treated with atenolol (abstract). J Heart Lung Transplant 2001;20:251.
70. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.
71. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
72. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-7.
73. Epstein M, Buckalew V, Martinez F, Altamirano J, Roniker B, Kleiman J, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/ enalapril combination therapy in diabetic hypertensives with microalbuminuria (abstract). Am J Hypertens 2002;15:24A.